Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

  • In development
  • GID-TA11439
  • Expected publication date: TBC

NIHRIO BN: 33651-Imlunestrant-for-Breast-Cancer-V1.0-SEP2023-NON-CONF-.pdf (nihr.ac.uk)